cost-effectiveness
NICE unveils five year plan promising faster access to medicines
Richard Staines
cost-effectiveness, market access, NICE, pricing
0 Comment
BMS’ MS pill gets funding in Scotland after rejection in England by NICE
Richard Staines
cost-effectiveness, market access, multiple sclerosis, neurology, SMC
0 Comment
NICE rejects BMS’ Zeposia MS pill in provisional guidance
Richard Staines
Bristol-Myers Squibb, cost-effectiveness, market access, multiple sclerosis, Roche, Zeposia
0 Comment
After two decades, NICE begins consultation on drug assessment methods
Richard Staines
cancer, cost-effectiveness, market access, NICE, Rare diseases
0 Comment
NICE rejects Sanofi’s Cablivi for rare blood disorder TTP
Richard Staines
cost-effectiveness, market access, NICE, Sanofi
0 Comment
Study sets benchmark for cost of repurposed coronavirus drugs
Phil Taylor
coronavirus, cost-effectiveness, Gilead, remdesivir
0 Comment
Market Access/ News/ News/ Oncology
NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use
Richard Staines
breast cancer, cancer, cost-effectiveness, Kadcyla, market access, NICE, Roche
0 Comment
News/ News/ Oncology/ Top stories
NICE rejects Roche’s Polivy combination in advanced lymphoma
Richard Staines
cost-effectiveness, diffuse B-Cell lymphoma, DLBCL, Gilead, lymphoma, NICE, Novartis, Roche
0 Comment